Devicare, member of CataloniaBio, especialized in innovative medical devices for home care of chronic patients under (Remote Patient Monitoring) has closed a seed round of 3 million euros. This funding will be used to consolidate the launch of clinical studies of two of Devicare's main product lines on the Spanish market: (Lit-Control®) for prevention and self-management of recurring urinary diseases and (Tao-Control®) for self-management of patients who take oral anticoagulants.

The company opened the entrance of investment holding company EMESA, and other Family Offices and Corporate partners. “This profile of investors is without a doubt a large strategic contribution to our company's growth”, says the comission coordinator on medical technology of CataloniaBio and founder and CEO of Devicare.

According to data by the Berg Insight, it is estimated that the number of patients monitored will reach 50.2 million in the next 4 years. "We are convinced that this is the way to improve healthcare management and the quality of life for patients who suffer from chronic diseases", explains Xavier Peris, sales and marketing director at Devicare.

More information on Devicare website

Photo: Rosendo Garganta, founder and CEO of Devicare